- Conditions
- Hemorrhage
- Interventions
- Kcentra®, Plasma
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Oakland, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Chronic Kidney Disease Stage 3 and 4
- Interventions
- Ergocalciferol, Cholecalciferol
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Atrial Fibrillation
- Interventions
- Apixaban, Acetylsalicylic acid
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 6,421 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 69
- States / cities
- Mobile, Alabama • Tucson, Arizona • Anaheim, California + 62 more
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- discontinue anticoagulation therapy, Anticoagulant drugs, Catheter Ablation
- Behavioral · Drug · Procedure
- Lead sponsor
- China National Center for Cardiovascular Diseases
- Government
- Eligibility
- 18 Years and older
- Enrollment
- 3,160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Deep Vein Thrombosis
- Interventions
- SanOrg34006, LMW heparin, Unfractionated heparin, Vitamin K antagonist (VKA)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 24
- States / cities
- Denver, Colorado • Jacksonville, Florida • Melbourne, Florida + 21 more
- Conditions
- Cardiovascular Diseases, Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 5, Vitamin K Deficiency, Hemodialysis
- Interventions
- Vitamin K2 (menaquinone-7; 360-mcg/d), Placebo-Control
- Dietary Supplement
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Venous Thromboembolism
- Interventions
- Xarelto (Rivaroxaban, BAY59-7939), (LMW) Heparin + Vitamin K Antagonist
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 543 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 5
- States / cities
- Albuquerque, New Mexico • Chapel Hill, North Carolina • Fredericksburg, Virginia + 1 more
- Conditions
- Osteo Arthritis Knee
- Interventions
- Vitamin K1 500 µg, K1 1000 µg, Vitamin K2 (MK-7) 300 µg, Placebo
- Drug · Other
- Lead sponsor
- Boston University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Atrial Fibrillation, Stroke, Bleeding
- Interventions
- WATCHMAN FLX Pro LAAC Device
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,857 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 78 more
- Conditions
- Atrial Fibrillation
- Interventions
- Dabigatran (Pradaxa), Vitamin K antagonist
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56,039 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Atrial Fibrillation
- Interventions
- rivaroxaban, uninterrupted vitamin K antagonist (VKA)
- Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 253 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 24
- States / cities
- Beverly Hills, California • Los Angeles, California • Sacramento, California + 21 more
- Conditions
- Venous Thromboembolism
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Standard of Care
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
- Conditions
- Atrial Fibrillation, Stroke, Bleeding
- Interventions
- WATCHMAN FLX LAAC Device, Non-Vitamin K Oral Anticoagulant
- Device · Drug
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 95
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 83 more
- Conditions
- Vitamin K-Dependent Coagulation Defect, Significant Bleeding Risk
- Interventions
- Balfaxar, Kcentra
- Drug
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,574 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Ecchymosis
- Interventions
- Petrolatum United States Pharmacopeia (USP), Vitamin K and retinol ointment, Arnica ointment, Vitamin K ointment
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 20 Years to 60 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Obesity, Insulin Resistance, Obesity in Diabetes, Nutritional and Metabolic Diseases, Hyperlipidemia, Hyperglycemia, Cardiovascular Diseases
- Interventions
- Placebo-Control, Low-Dose Vitamin K2 (menaquinone-7; 45-mcg/d), High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)
- Dietary Supplement
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Coagulation Delay
- Interventions
- phytonadione
- Dietary Supplement
- Lead sponsor
- James A. Haley Veterans Administration Hospital
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 370 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Stroke, Atrial Fibrillation
- Interventions
- Non-vitamin K oral anticoagulant (NOAC)
- Drug
- Lead sponsor
- Population Health Research Institute
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 2,270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Houston, Texas
- Conditions
- Cholesterol Lowering
- Interventions
- Sugar Pill, Chinese Red Yeast Rice (CRYR), CRYR + TRF, Tocotrienol-enriched Fraction of Palm Oil (TRF)
- Drug · Device
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 35 Years to 70 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Psoriasis
- Interventions
- Drug Cocktail, Mirikizumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Anaheim, California • DeLand, Florida • High Point, North Carolina
- Conditions
- Atrial Fibrillation, Percutaneous Coronary Intervention
- Interventions
- rivaroxaban 2.5 mg, rivaroxaban 15 mg, rivaroxaban 10 mg, aspirin (ASA), vitamin K antagonist (VKA), clopidogrel, prasugrel, ticagrelor
- Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 86
- States / cities
- Huntsville, Alabama • Los Alamitos, California • Mission Viejo, California + 83 more
- Conditions
- Psoriasis
- Interventions
- Drug Cocktail, Ixekizumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 3
- States / cities
- Anaheim, California • DeLand, Florida • High Point, North Carolina
- Conditions
- Atrial Fibrillation
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), VKA (Vitamin K antagonist)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38,831 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Reversal of Coagulopathy
- Interventions
- Beriplex® P/N (Kcentra), Fresh frozen plasma
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 16
- States / cities
- Newark, Delaware • Lexington, Kentucky • Boston, Massachusetts + 13 more